Quarterly report pursuant to Section 13 or 15(d)

Restructuring Charges

v3.7.0.1
Restructuring Charges
3 Months Ended
Mar. 31, 2017
Restructuring And Related Activities [Abstract]  
Restructuring Charges

7. Restructuring Charges

 

On December 19, 2016, the Board of Directors approved a restructuring of its business based on its decision to focus the Company’s efforts on clinical development, with an initial focus on the X358 clinical programs. The restructuring included a reduction-in-force in which the Company terminated 57 employees (the “2016 Restructuring”). In addition, effective December 21, 2016, the Company’s Chief Executive Officer retired from his position. In early 2017, the Company further revised its strategy to prioritize out-licensing activities and further curtail research and development spending (the “2017 Restructuring”), and the Company expects to eliminate five additional employees with an effective termination date of June 30, 2017.

During the three months ended March 31, 2017, the Company recorded charges of $0.5 million and $1.5 million related to severance, other termination benefits and outplacement services in connection with the workforce reductions resulting from the 2017 Restructuring and 2016 Restructuring, respectively. In the first quarter of 2017, the Company paid a total of $3.8 million associated with the 2017 Restructuring and 2016 Restructuring activities. Of the remaining accrued restructuring of $1.8 million, the Company expects to pay $1.0 million in the second quarter of 2017 and the remaining $0.8 million related to executive severance will continue to be paid through March 2018.   

 

The following table summarizes the accrued restructuring costs on the condensed consolidated balance sheet as of March 31, 2017 (in thousands):

 

 

 

Employee Severance

 

 

 

and Other Benefits

 

Balance at December 31, 2016

 

$

3,594

 

Restructuring charges

 

 

2,020

 

Cash payments

 

 

(3,821

)

Balance at March 31, 2017

 

$

1,793